SCHEMBL5029392

SCHEMBL5029392

Fc1cccc(F)c1/C=N/Nc1ccc(-c2cc(-c3ncco3)ccc2Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.43
NPC1 O15118 5/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTT P42858 1/20 0.38
IL2 P60568 3/20 0.38
GAA P10253 5/20 0.37
MAPT P10636 3/20 0.37
GFER P55789 2/20 0.37
MEN1 O00255 6/20 0.35
KMT2A Q03164 6/20 0.35
POLB P06746 2/20 0.33
THRB P10828 1/20 0.33
P2RX7 Q99572 1/20 0.33
FAAH O00519 1/20 0.33
EPHX2 P34913 1/20 0.33
PKM P14618 1/20 0.33
ALDH1A1 P00352 2/20 0.32
HPGD P15428 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5029395 1.00 RAB9A (0.43) RAB9ANPC1SMN1; SMN2LMNAL3MBTL1
SCHEMBL5029757 0.88 IL2 (0.48) RAB9ANPC1SMN1; SMN2LMNAL3MBTL1
SCHEMBL5029759 0.88 IL2 (0.48) RAB9ANPC1SMN1; SMN2LMNAL3MBTL1
SCHEMBL5027342 0.77 SMN1; SMN2 (0.47) RAB9ANPC1SMN1; SMN2LMNAL3MBTL1
SCHEMBL5527953 0.77 SMN1; SMN2 (0.47) RAB9ANPC1SMN1; SMN2LMNAL3MBTL1
SCHEMBL4767793 0.76 IL2 (0.61) RAB9AHTTIL2GAAMAPT
SCHEMBL5029432 0.76 SGK1 (0.45) RAB9ANPC1IL2GAAFAAH
SCHEMBL5027336 0.72 IL2 (0.48) LMNAHTTIL2MAPTMEN1
SCHEMBL5027329 0.72 IL2 (0.48) LMNAHTTIL2MAPTMEN1
SCHEMBL14377331 0.71 SGK1 (0.36) IL2FAAHEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741960-B2 Substituted aromatic compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2014-06-03 US claimed
US-20070249050-A1 Substituted aromatic compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-10-25 US claimed
US-20140242120-A1 SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2014-08-28 US disclosed
US-20140242120-A1 SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2014-08-28 US disclosed
US-8741960-B2 Substituted aromatic compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2014-06-03 US disclosed
US-8741960-B2 Substituted aromatic compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2014-06-03 US disclosed
US-8741960-B2 Substituted aromatic compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2014-06-03 US disclosed
EP-1983971-A2 SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2008-10-29 EP disclosed
US-20070249050-A1 Substituted aromatic compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-10-25 US disclosed
US-20070249050-A1 Substituted aromatic compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-10-25 US disclosed
US-20070249050-A1 Substituted aromatic compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-10-25 US disclosed
WO-2007087441-A2 SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-08-02 WO disclosed
WO-2007087441-A2 SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249050-A1 Substituted aromatic compounds for inflammation and immune-related uses CCR1, NLRP1, NLRP3 RAB9A 1795/4885NPC1 634/4885SMN1; SMN2 4703/4885
US-20140242120-A1 SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES CCR1, NLRP1, NLRP3 RAB9A 1795/4885NPC1 634/4885SMN1; SMN2 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.